Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.

Background: FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib in previously treated patients with FGFR-altered advanced solid tumours.

[Paroxysmal upgaze deviation syndrome].

In 1988, Ouvrier and Billson described four children with a condition they termed "benign paroxysmal tonic upgaze syndrome". The clinical picture is characterized by the appearance, in the first months of life, of episodes of paroxysmal upgaze deviation of varying duration, and without alteration of consciousness. Fixation nystagmus is observed when trying to look down.

[Home hospitalization for patients with acute illnesses].

This study presents the results of 26 months of work, from January 1996 through February 1998, of the Distinct Home Hospitalization Service for Acute Patients. This service managed 20 home beds with two teams, each with a physician and a nurse, with a care approach similar to that for a room in a hospital. Among the items evaluated were the attributes of the admitted population, their illnesses, the form of administering drugs, the satisfaction of the caregivers, the indices of performance, and the costs with this approach.